Infliximab treatment in pathology-confirmed neurosarcoidosis
Open Access
- 3 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 7 (5)
Abstract
Objective To assess the efficacy and risks of treatment with infliximab (anti–tumor necrosis factor alpha) in pathology-confirmed neurosarcoidosis. Methods In a retrospective study in 2 tertiary referral centers in the Netherlands, we analyzed clinical characteristics, complications, and outcome of patients with neurosarcoidosis treated with infliximab. Results Twenty-eight patients were identified with a mean age of 42 years. Neurosarcoidosis presented with a cerebral parenchymal localization in 16 (59%), pituitary gland/hypothalamic sarcoidosis in 15 (54%), peripheral nerve involvement in 12 (43%), and chronic meningitis in 11 patients (41%). Initial treatment response after the start of infliximab was complete remission in 6 (21%) and improvement in 14 (50%), whereas 7 patients had stable disease (25%), and 1 (4%) deteriorated and died. At the end of follow-up, with a median of 32 months, 5 patients (18%) had died, and 2 (40%) were using infliximab at the time of death. Tapering or discontinuation of corticosteroids without a relapse was achieved in 19 of 28 patients (68%). In patients with decreasing dosing or discontinuation of infliximab, a relapse occurred in 5 of 19 patients (26%). Complications of infliximab were reported in 10 of 28 patients (36%) and mainly consisted of infections in 8 (29%). Conclusion Infliximab is an effective treatment in neurosarcoidosis leading to remission or improvement in 70%. The mortality rate in infliximab-treated patients was substantial, indicating the severity of disease and treatment-associated complications. Classification of evidence This study provides Class IV evidence that in people with pathology-confirmed neurosarcoidosis, infliximab is beneficial.Keywords
This publication has 30 references indexed in Scilit:
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysisAnnals of the Rheumatic Diseases, 2013
- Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapySeminars in Arthritis and Rheumatism, 2013
- Long-Term Treatment with Infliximab in Patients with SarcoidosisRespiration, 2011
- Clinical outcomes in sarcoidosis after cessation of infliximab treatmentRespirology, 2009
- Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosisRespiratory Medicine, 2009
- Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetilNeurology, 2009
- Treatment of refractory neurosarcoidosis with InfliximabJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in preventionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary InvolvementAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003